Autologous cell therapy market seen reaching $27.31 billion by 2030

The Business Research Company says the autologous cell therapy market will grow from $12.14 billion in 2025 to $27.31 billion by 2030, driven by chronic disease demand, oncology use and faster manufacturing. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Autologous cell therapy is gaining traction as a personalized treatment approach for patients with hard-to-treat conditions. - The market’s projected growth points to rising demand for regenerative medicine, oncology applications and patient-specific therapies. - The expansion could accelerate investment in cell processing, clinical trials and manufacturing automation.

What happened: - The Business Research Company published its Autologous Cell Therapy Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report says the market will rise from $12.14 billion in 2025 to $14.28 billion in 2026, a 17.6% compound annual growth rate. - The market is projected to reach $27.31 billion by 2030, continuing at a 17.6% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Autologous cell therapy uses a patient’s own cells, processes them outside the body and reintroduces them to support healing or restore damaged tissues and organs. - The report ties market growth to progress in stem cell research, early clinical results, higher chronic disease rates, broader oncology treatment options and more investment in regenerative medicine. - More frequent approvals of cell-based therapies are expected to support further market growth. - Growing demand for tailored medical solutions is another stated driver. - Advancements in manufacturing automation for cell therapies are expected to help scale production. - More clinical trial activity is adding momentum to the sector. - Rising healthcare spending on cutting-edge therapies is also supporting expansion. - Key trends include wider use of CAR T-cell therapies, personalized regenerative treatments, automated cell processing technologies and broader applications of autologous stem cells. - The report also highlights a stronger focus on patient-specific therapeutic outcomes. - The market analysis includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company also offers a free sample of the report here. - The full report is available here.

Between the lines: - Chronic disease burden appears to be a core demand engine, especially as older populations need more long-term treatment options. - The report’s emphasis on automation and manufacturing suggests the sector’s growth depends not just on science, but also on the ability to produce therapies at scale. - North America’s lead reflects stronger infrastructure and faster adoption of advanced therapies, while Asia-Pacific’s growth outlook signals widening global competition.

What's next: - More cell-based therapy approvals could help the market expand toward the 2030 forecast. - Clinical trial activity and automation advances are likely to remain key indicators of how quickly the sector scales. - Rising healthcare spending on advanced therapies could further support commercialization and broader adoption. - The report’s longer-range forecast through 2035 suggests continued growth beyond the 2030 milestone.